No – not that apprentice. This week we had the pleasure of speaking with Todd Brady, MD/PhD turned VC/EIR turned CEO of Aldeyra back in 2012. 

Todd talks about how he transitioned from the lab over to the dark side back in the 90s when “Industry” was still a dirty word. 

Todd found his calling as a company builder who has since taken Aldeyra public and into Phase 3 trials with novel treatments for dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy. 

The company is also developing other product candidates for retinal and systemic inflammatory diseases. Listen in for some words of wisdom from the real Apprentice…